A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Bristoll Myers Squibb
Start Date
February 28, 2022
End Date
October 2, 2026
Administered By
Duke Cancer Institute
Awarded By
Bristoll Myers Squibb
Start Date
February 28, 2022
End Date
October 2, 2026